Galectin Therapeutics Inc. (GALT)
Summary
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and clarifies regulatory endpoints. The FDA's endorsement of a single, well-controlled Phase 3 trial with a composite clinical outcome endpoint reduces uncertainty and shortens timelines. GALT's valuation reflects skepticism about execution, financing risk, and commercial viability, but successful Phase 3 results could trigger a significant re-rating.
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galectin Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YA Yinka Akinsola Blue Trust Inc. | 7,000 | $10,610 | $33,845 | $23,235 | 218.99% |
| SE Sima Elimelech Activest Wealth Management | 2,000 | $4,520 | $9,520 | $5,000 | 110.62% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 22,500 | $62,775 | $109,575 | $46,800 | 74.55% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 3,890 | $9,669.66 | $18,885.95 | $9,216.29 | 95.31% |
| NB Nolan Baker Retirement Guys Formula LLC | 187,062 | $385,404.06 | $866,097.06 | $480,693 | 124.72% |
Galectin Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MK Matthew Keller HC Wainwright & Co. | 11,848.34 | $36,966.82 | $56,398.1 | $19,431.28 | 52.56% |
Galectin Therapeutics Inc. (GALT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Galectin Therapeutics Inc. ever had a stock split?
Galectin Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Joel Lewis CEO | NASDAQ (CM) Exchange | 363225202 CUSIP |
| US Country | 9 Employees | - Last Dividend | 23 Mar 2012 Last Split | 9 Sep 2002 IPO Date |
Overview
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for fibrotic diseases, cancer, and other serious conditions. Established in 2000 and originally known as Pro-Pharmaceuticals, Inc., the company underwent a name change in May 2011 to better reflect its specialized focus on galectin proteins, particularly the galectin-3 inhibitor. Galectin Therapeutics operates from its headquarters in Norcross, Georgia, and expands its research capabilities through a collaborative joint venture, Galectin Sciences, LLC, co-owned with SBH Sciences, Inc. This collaboration is dedicated to the research and development of small organic molecule inhibitors of galectin-3, indicating Galectin Therapeutics' commitment to leading-edge research in galectin protein inhibition.
Products and Services
- Belapectin (GR-MD-02)
As the lead product candidate of Galectin Therapeutics, belapectin is a pioneering galectin-3 inhibitor. This therapeutic agent is a complex polysaccharide polymer designed to target and mitigate the effects of galectin-3, a protein implicated in various fibrotic and malignant diseases. Currently, belapectin is in Phase III clinical trials, showing promise for treating liver fibrosis associated with fatty liver disease, including non-alcoholic steatohepatitis (NASH) cirrhosis. Additionally, it is under investigation for its applicability in treating cancer, signifying its potential as a versatile therapeutic agent.
- Small Organic Molecule Inhibitors of Galectin-3
Through Galectin Sciences, LLC, a joint venture with SBH Sciences, Inc., Galectin Therapeutics is also exploring the potential of small organic molecule inhibitors of galectin-3 for oral administration. This research aims at expanding the company's portfolio to include orally available therapies that can inhibit galectin-3, offering a convenient and accessible treatment option for patients suffering from diseases associated with this protein.
